AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 22244510 — intervention group
Group type: EXPERIMENTAL
Intervention: Patellar tendon graft
Number of subjects: 48
Study 22244510 — intervention group
Group type: EXPERIMENTAL
Intervention: Hamstring graft
Number of subjects: 48
Study 22244510 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 48
Study 20190541 — intervention group
Group type: EXPERIMENTAL
Intervention: Thyroxine treatment
Number of subjects: 50
Study 20190541 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 50
Study 18552701 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic surgery (Group A, n = 113)
Number of subjects: 226
Study 18552701 — intervention group
Group type: COMPARATOR
Intervention: Conservative treatment (Group B, n = 113)
Number of subjects: 226
Study 15776337 — intervention group
Group type: EXPERIMENTAL
Intervention: Backward run/walk training program for six weeks
Number of subjects: 26
Study 15776337 — intervention group
Group type: COMPARATOR
Intervention: Control group restricted to daily activities
Number of subjects: 26
Study 12434840 — intervention group
Group type: EXPERIMENTAL
Intervention: Processing of psalm-type words (silent letter condition)
Number of subjects: 0
Study 12434840 — intervention group
Group type: COMPARATOR
Intervention: Processing of pasta-type words (nonsilent letter condition)
Number of subjects: 0
Study 10622543 — intervention group
Group type: EXPERIMENTAL
Intervention: Papaverine injection
Number of subjects: 75
Study 10622543 — intervention group
Group type: COMPARATOR
Intervention: Isotonic saline injection
Number of subjects: 75
Study 10622543 — intervention group
Group type: COMPARATOR
Intervention: No injection
Number of subjects: 75
Study 7782057 — intervention group
Group type: EXPERIMENTAL
Intervention: Purified urinary follicle‐stimulating hormone (uFSH‐HP; Metrodin HP®) in standard IVF
Number of subjects: 11
Study 7782057 — intervention group
Group type: COMPARATOR
Intervention: Combination of pure FSH and human menopausal gonadotrophin (hMG; Pergonal®) in standard IVF
Number of subjects: 11
Study 7782057 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant FSH (Gonal F®) in ICSI
Number of subjects: 11
Study 7782057 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard IVF vs ICSI
Number of subjects: 11
Study 2209234 — intervention group
Group type: EXPERIMENTAL
Intervention: Defibrase (DF) 0.05 u or 0.075 u/kg over 1 hour immediately after the attack and 0.025 u/kg over 4 hours on the 5th and 10th day
Number of subjects: 21
Study 2209234 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy only
Number of subjects: 21
Study 2209234 — intervention group
Group type: EXPERIMENTAL
Intervention: Defibrase (DF)
Number of subjects: 21
Study 446284 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine
Number of subjects: 38
Study 446284 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study 31442498 — intervention group
Group type: EXPERIMENTAL
Intervention: Esophagectomy alone
Number of subjects: 13365
Study 31442498 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant therapy
Number of subjects: 13365
Study 31442498 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimal therapy (predicted)
Number of subjects: 13365
Study 31442498 — intervention group
Group type: EXPERIMENTAL
Intervention: Actual therapy received
Number of subjects: 13365
Study 30139336 — intervention group
Group type: EXPERIMENTAL
Intervention: Community coaching by Extension Educators/field staff, FPC development, and development of a MyChoice food pantry (intervention group).
Number of subjects: 24
Study 30139336 — intervention group
Group type: COMPARATOR
Intervention: Comparison group (no community coaching).
Number of subjects: 24
Study 26840852 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent ACP intervention program (integrating motivational interviewing, evidence‐based ACP facilitation program, and health‐literacy adjusted AD)
Number of subjects: 30
Study 26840852 — intervention group
Group type: COMPARATOR
Intervention: Educational material (control group)
Number of subjects: 30
Study 24507657 — intervention group
Group type: COMPARATOR
Intervention: TRO40303 (0.5 to 13 mg/kg)
Number of subjects: 72
Study 24507657 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study 20676646 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium hyaluronate injection (SH)
Number of subjects: 24
Study 20676646 — intervention group
Group type: COMPARATOR
Intervention: Physical therapy modalities (PTM)
Number of subjects: 24
Study 20179559 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral midazolam (0.2 mg/kg)
Number of subjects: 42
Study 20179559 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 17331930 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mL 6% hydroxyethyl starch (HES)
Number of subjects: 30
Study 17331930 — intervention group
Group type: COMPARATOR
Intervention: 1500 mL lactated Ringer's (LR)
Number of subjects: 30
Study 16392462 — intervention group
Group type: EXPERIMENTAL
Intervention: Written exercise sheet (Group 1)
Number of subjects: 64
Study 16392462 — intervention group
Group type: COMPARATOR
Intervention: No exercise sheet (Group 2)
Number of subjects: 64
Study 12020186 — intervention group
Group type: EXPERIMENTAL
Intervention: Community pharmacist intervention (education, brochure on risk factors, point-of-care cholesterol measurement, referral to physician, regular follow-up for 16 weeks)
Number of subjects: 675
Study 12020186 — intervention group
Group type: COMPARATOR
Intervention: Usual care (brochure and general advice only, minimal follow-up)
Number of subjects: 675
Study 11675809 — intervention group
Group type: EXPERIMENTAL
Intervention: Workbook intervention
Number of subjects: 376
Study 11675809 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer intervention
Number of subjects: 376
Study 11675809 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 376
Study 9731025 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective decontamination of the digestive tract (SDD)
Number of subjects: 271
Study 9731025 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 271
Study 7846196 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolpidem 10 mg IV as a 3-min infusion
Number of subjects: 12
Study 7846196 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolpidem 20 mg orally
Number of subjects: 12
Study 7846196 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolpidem 5 mg IV
Number of subjects: 12
Study 7846196 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolpidem 5 mg orally
Number of subjects: 12
Study 7846196 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 2454514 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostacyclin 5 ng kg‐1 min‐1
Number of subjects: 6
Study 2454514 — intervention group
Group type: EXPERIMENTAL
Intervention: Iloprost 2 ng kg‐1 min‐1
Number of subjects: 6
Study 2454514 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 1204500 — intervention group
Group type: EXPERIMENTAL
Intervention: Attenuated influenza-A-virus strain 'Alice' (H3N2), given intransally in drops (10(7,2) ID50 per dose), twice seven days apart
Number of subjects: 25
Study 1204500 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 1204500 — intervention group
Group type: EXPERIMENTAL
Intervention: Attenuated influenza-A-virus strain 'Alice' (H3N2)
Number of subjects: 25
Study 1204500 — intervention group
Group type: COMPARATOR
Intervention: Inactivated virus vaccine
Number of subjects: 25
Study 30553764 — intervention group
Group type: EXPERIMENTAL
Intervention: CHO‐BD
Number of subjects: 11
Study 30553764 — intervention group
Group type: COMPARATOR
Intervention: CHO
Number of subjects: 11
Study 28301620 — intervention group
Group type: EXPERIMENTAL
Intervention: CeraVe Itch Relief Lotion and Cream (1% pramoxine hydroxide)
Number of subjects: 66
Study 28301620 — intervention group
Group type: EXPERIMENTAL
Intervention: CeraVe Itch Relief Cream (1% pramoxine hydrochloride)
Number of subjects: 66
Study 28301620 — intervention group
Group type: COMPARATOR
Intervention: Hydrocortisone 1% cream
Number of subjects: 66
Study 28301620 — intervention group
Group type: EXPERIMENTAL
Intervention: CeraVe Itch Relief Cream (1% pramoxine hydrochloride) used daily over 6 days
Number of subjects: 66
Study 25082954 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic interval training (AIT)
Number of subjects: 70
Study 25082954 — intervention group
Group type: COMPARATOR
Intervention: Low energy diet (LED)
Number of subjects: 70
Study 25082954 — intervention group
Group type: EXPERIMENTAL
Intervention: Both AIT and LED
Number of subjects: 70
Study 23329885 — intervention group
Group type: EXPERIMENTAL
Intervention: Guanidinoacetic acid (GAA) 2.4 grams daily
Number of subjects: 24
Study 23329885 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 24
Study 22077689 — intervention group
Group type: EXPERIMENTAL
Intervention: CEM (Calcium-Enriched Mixture)
Number of subjects: 40
Study 22077689 — intervention group
Group type: COMPARATOR
Intervention: MTA (Mineral Trioxide Aggregate)
Number of subjects: 40
Study 22077689 — intervention group
Group type: EXPERIMENTAL
Intervention: CEM
Number of subjects: 40
Study 22077689 — intervention group
Group type: COMPARATOR
Intervention: MTA
Number of subjects: 40
Study 22077689 — intervention group
Group type: EXPERIMENTAL
Intervention: CEM and MTA
Number of subjects: 40
Study 19806264 — intervention group
Group type: EXPERIMENTAL
Intervention: rFXIII-A(2) (11.9, 25, 35 or 50 IU/kg)
Number of subjects: 43
Study 19806264 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study 19806264 — intervention group
Group type: EXPERIMENTAL
Intervention: rFXIII-A(2) (35 IU/kg)
Number of subjects: 43
Study 19806264 — intervention group
Group type: EXPERIMENTAL
Intervention: rFXIII-A(2) (25-50 IU/kg)
Number of subjects: 43
Study 16397287 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus tablet
Number of subjects: 477
Study 16397287 — intervention group
Group type: COMPARATOR
Intervention: Sirolimus solution
Number of subjects: 477
Study 14965840 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemoperfusion plus hemodialysis (HP+HD)
Number of subjects: 40
Study 14965840 — intervention group
Group type: COMPARATOR
Intervention: Hemodialysis (HD)
Number of subjects: 40
Study 11342952 — intervention group
Group type: EXPERIMENTAL
Intervention: No dressing
Number of subjects: 120
Study 11342952 — intervention group
Group type: COMPARATOR
Intervention: Adhesive biomembrane dressing
Number of subjects: 120
Study 11342952 — intervention group
Group type: COMPARATOR
Intervention: Compressive wrap dressing
Number of subjects: 120
Study 9170048 — intervention group
Group type: EXPERIMENTAL
Intervention: Breath-holding after breathing room air
Number of subjects: 118
Study 9170048 — intervention group
Group type: EXPERIMENTAL
Intervention: Breath-holding after hyperventilation of room air
Number of subjects: 118
Study 9170048 — intervention group
Group type: EXPERIMENTAL
Intervention: Breath-holding after O2 administration
Number of subjects: 118
Study 8223829 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine
Number of subjects: 20
Study 8223829 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 3536677 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous metronidazole 500 mg eight hourly (19 patients)
Number of subjects: 39
Study 3536677 — intervention group
Group type: COMPARATOR
Intervention: Identical intravenous placebo (20 patients)
Number of subjects: 39
Study 3536677 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous metronidazole
Number of subjects: 39
Study 3536677 — intervention group
Group type: COMPARATOR
Intervention: Identical intravenous placebo
Number of subjects: 39
Study 31673234 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl
Number of subjects: 64
Study 31673234 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufentanil
Number of subjects: 64
Study 30019181 — intervention group
Group type: EXPERIMENTAL
Intervention: Within school schedule intervention group
Number of subjects: 837
Study 30019181 — intervention group
Group type: EXPERIMENTAL
Intervention: After-school intervention group
Number of subjects: 837
Study 30019181 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 837
Study 27097575 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate aerosol (flixotide)
Number of subjects: 214
Study 27097575 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide suspension
Number of subjects: 214
Study 27097575 — intervention group
Group type: COMPARATOR
Intervention: Control group (no regular inhalation of corticosteroid)
Number of subjects: 214
Study 24449009 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-frequency noise band (0.375-0.75 kHz)
Number of subjects: 2
Study 24449009 — intervention group
Group type: EXPERIMENTAL
Intervention: High-frequency noise band (2.25-4.5 kHz)
Number of subjects: 2
Study 24449009 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimum audible angle (MAA) thresholds
Number of subjects: 2
Study 24449009 — intervention group
Group type: EXPERIMENTAL
Intervention: Localization accuracy
Number of subjects: 2
Study 22077816 — intervention group
Group type: EXPERIMENTAL
Intervention: Vorapaxar
Number of subjects: 12944
Study 22077816 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12944
Study 19945103 — intervention group
Group type: EXPERIMENTAL
Intervention: Uterine artery ligation
Number of subjects: 103
Study 19945103 — intervention group
Group type: COMPARATOR
Intervention: Pericervical tourniquet
Number of subjects: 103
Study 17490672 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 ng/kg LPS intravenously
Number of subjects: 36
Study 17490672 — intervention group
Group type: COMPARATOR
Intervention: Physiologic saline solution (placebo)
Number of subjects: 36
Study 15550496 — intervention group
Group type: COMPARATOR
Intervention: 5.0 mm conventional instruments
Number of subjects: 480
Study 15550496 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.5 mm mini-instruments
Number of subjects: 480
Study 15550496 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal deliveries
Number of subjects: 480
Study 15550496 — intervention group
Group type: EXPERIMENTAL
Intervention: Experienced surgeons
Number of subjects: 480
Study 12499334 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A (retinyl palmitate) added to corn bread
Number of subjects: 5
Study 12499334 — intervention group
Group type: COMPARATOR
Intervention: Corn bread served with water
Number of subjects: 5
Study 12499334 — intervention group
Group type: COMPARATOR
Intervention: Corn bread served with coffee
Number of subjects: 5
Study 11220545 — intervention group
Group type: EXPERIMENTAL
Intervention: Medtronic Kappa 700(Europe)/Kappa 400(North America) pacemaker
Number of subjects: 0
Study 11220545 — intervention group
Group type: COMPARATOR
Intervention: Implantable loop recorder (ILR)
Number of subjects: 0
Study 8594515 — intervention group
Group type: EXPERIMENTAL
Intervention: Brovincamine fumarate (20 mg 3 times daily)
Number of subjects: 28
Study 8594515 — intervention group
Group type: COMPARATOR
Intervention: Placebo (3 times daily)
Number of subjects: 28
Study 2015119 — intervention group
Group type: EXPERIMENTAL
Intervention: Group aerobic exercise training
Number of subjects: 308
Study 2015119 — intervention group
Group type: COMPARATOR
Intervention: Group light exercise
Number of subjects: 308
Study 6961759 — intervention group
Group type: EXPERIMENTAL
Intervention: Labetalol 200 mg daily
Number of subjects: 24
Study 3907824 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide 60 mg
Number of subjects: 112
Study 3907824 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide 120 mg
Number of subjects: 112
Study 3907824 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin treatment
Number of subjects: 112
Study 29850782 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan/Amlodipine combination therapy (80/5 mg) for 16 weeks
Number of subjects: 23
Study 27444761 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine jelly
Number of subjects: 99
Study 27444761 — intervention group
Group type: EXPERIMENTAL
Intervention: Betamethasone gel
Number of subjects: 99
Study 27444761 — intervention group
Group type: COMPARATOR
Intervention: Distilled water
Number of subjects: 99
Study 27444761 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 99
Study 24950172 — intervention group
Group type: EXPERIMENTAL
Intervention: Guilt-inducing condition (game play as a terrorist)
Number of subjects: 0
Study 24950172 — intervention group
Group type: COMPARATOR
Intervention: Control condition (game play as a UN soldier)
Number of subjects: 0
Study 22789773 — intervention group
Group type: EXPERIMENTAL
Intervention: Video-based therapy at home for patients with stroke (3 months duration)
Number of subjects: 90
Study 22789773 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy (weekly outpatient therapy sessions)
Number of subjects: 90
Study 20565152 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based personalized feedback intervention
Number of subjects: 341
Study 20565152 — intervention group
Group type: COMPARATOR
Intervention: Assessment-only control
Number of subjects: 341
Study 18386569 — intervention group
Group type: EXPERIMENTAL
Intervention: Allicin via gastroscopy
Number of subjects: 80
Study 18386569 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (Control)
Number of subjects: 80
Study 16644783 — intervention group
Group type: COMPARATOR
Intervention: Infliximab (16 weeks)
Number of subjects: 164
Study 16644783 — intervention group
Group type: COMPARATOR
Intervention: Etanercept (12 weeks)
Number of subjects: 164
Study 16644783 — intervention group
Group type: COMPARATOR
Intervention: Pooled indices (DAS and DAS28)
Number of subjects: 164
Study 11445622 — intervention group
Group type: EXPERIMENTAL
Intervention: nicardipine
Number of subjects: 14
Study 11445622 — intervention group
Group type: EXPERIMENTAL
Intervention: labetalol
Number of subjects: 14
Study 9817115 — intervention group
Group type: EXPERIMENTAL
Intervention: Belgian Dutch translation of the SF-36 Health Survey
Number of subjects: 4448
Study 9817115 — intervention group
Group type: EXPERIMENTAL
Intervention: Belgian French translation of the SF-36 Health Survey
Number of subjects: 4448
Study 9817115 — intervention group
Group type: EXPERIMENTAL
Intervention: SF-36 scale scores
Number of subjects: 4448
Study 9817115 — intervention group
Group type: EXPERIMENTAL
Intervention: Change in SF-36 scale scores over 6 months
Number of subjects: 4448
Study 9817115 — intervention group
Group type: EXPERIMENTAL
Intervention: French-speaking patients
Number of subjects: 4448
Study 9817115 — intervention group
Group type: EXPERIMENTAL
Intervention: Average change in SF-36 scale scores
Number of subjects: 4448
Study 8061995 — intervention group
Group type: EXPERIMENTAL
Intervention: Supine lateral dual X‐ray absorptiometry (DXA) with baseline compensation
Number of subjects: 12
Study 8061995 — intervention group
Group type: COMPARATOR
Intervention: Supine lateral dual X‐ray absorptiometry (DXA) without baseline compensation
Number of subjects: 12
Study 8061995 — intervention group
Group type: EXPERIMENTAL
Intervention: Supine lateral dual X‐ray absorptiometry (DXA) with multiplicative algorithm
Number of subjects: 12
Study 8061995 — intervention group
Group type: EXPERIMENTAL
Intervention: Supine lateral dual X‐ray absorptiometry (DXA) for L2‐L4
Number of subjects: 12
Study 8061995 — intervention group
Group type: EXPERIMENTAL
Intervention: Supine lateral dual X‐ray absorptiometry (DXA) for individual vertebrae
Number of subjects: 12
Study 3354802 — intervention group
Group type: EXPERIMENTAL
Intervention: Caudal injection of 1 ml/kg bupivacaine 0.25%
Number of subjects: 50
Study 3354802 — intervention group
Group type: COMPARATOR
Intervention: Wound infiltration of 0.5 ml/kg bupivacaine 0.25%
Number of subjects: 50
Study 28800141 — intervention group
Group type: COMPARATOR
Intervention: Ketoconazole
Number of subjects: 88
Study 28800141 — intervention group
Group type: COMPARATOR
Intervention: Clarithromycin
Number of subjects: 88
Study 28800141 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifampin
Number of subjects: 88
Study 27486141 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (24-48 IU/day)
Number of subjects: 25
Study 27486141 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 25136015 — intervention group
Group type: EXPERIMENTAL
Intervention: GSK1322322 at 1,500 mg b.i.d.
Number of subjects: 75
Study 25136015 — intervention group
Group type: COMPARATOR
Intervention: Linezolid at 600 mg b.i.d.
Number of subjects: 75
Study 23174463 — intervention group
Group type: EXPERIMENTAL
Intervention: Interpersonal psychotherapy group (IPT-G)
Number of subjects: 304
Study 23174463 — intervention group
Group type: COMPARATOR
Intervention: Creative play/recreation group
Number of subjects: 304
Study 23174463 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control condition
Number of subjects: 304
Study 20517868 — intervention group
Group type: EXPERIMENTAL
Intervention: Human Albumin Grifols 5%
Number of subjects: 29
Study 20517868 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 29
Study 18452826 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostate-specific antigen (PSA) screening
Number of subjects: 0
Study 18452826 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of PSA with other markers or tests
Number of subjects: 0
Study 18452826 — intervention group
Group type: EXPERIMENTAL
Intervention: Observational studies of PSA benefit
Number of subjects: 0
Study 18452826 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer models for inferring impact of screening
Number of subjects: 0
Study 16292207 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab combined with chemotherapy
Number of subjects: 0
Study 16292207 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 0
Study 16292207 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetuximab for pretreated colorectal cancer
Number of subjects: 0
Study 11866009 — intervention group
Group type: EXPERIMENTAL
Intervention: Nacystelyn (NAL) 24 mg (12 puffs)
Number of subjects: 22
Study 11866009 — intervention group
Group type: COMPARATOR
Intervention: Placebo (12 puffs)
Number of subjects: 22
Study 11866009 — intervention group
Group type: EXPERIMENTAL
Intervention: Nacystelyn (NAL) (4 mg to 16 mg, varying doses)
Number of subjects: 22
Study 11866009 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 10212885 — intervention group
Group type: EXPERIMENTAL
Intervention: Massage therapy
Number of subjects: 26